ALX Oncology Holdings Inc (NAS:ALXO)
$ 8.21 -0.23 (-2.73%) Market Cap: 427.74 Mil Enterprise Value: 291.47 Mil PE Ratio: 0 PB Ratio: 2.51 GF Score: 33/100

ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 08, 2021 / 07:40PM GMT
Release Date Price: $52.12 (+2.28%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

All right. Perfect. So welcome, everyone, to the 30th Annual Healthcare Conference of Crédit Suisse. I'm Tiago Fauth. I'm a biotech analyst here at Crédit Suisse. We're joined today by ALX Oncology for a fireside chat. Feel free to e-mail me any questions that you guys want to try to -- I'll try to work those in.

We're joined today by Jaume Pons and Sophia Randolph from ALX Oncology. And basically, we can always start with some brief remarks on some of the highlights of 2021 for ALX Oncology so far. We're going to talk a little bit about the competitive landscape and then dive in to some recent data updates.

But Jaume, you can take it away for a brief intro and I'll -- we'll follow from that.

Jaume Pons
ALX Oncology Holdings Inc. - President, CEO & Director

Yes. So I think that this year has been a good year for us. We have a lot of data coming out, and we have started many Phase II and other trials that we've been in for years. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot